13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Page 4 of 9 – SEC Filing

CUSIP No. 253031108

1

Names of Reporting Persons.

RA Capital Healthcare Fund, L.P.

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3 SEC Use Only
4

Source of Funds (See Instructions):

WC

5

Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):

¨

6

Citizenship or Place of Organization.
   Delaware

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7

Sole
Voting Power    0 shares

8

Shared
Voting Power    4,018,603 shares

9

Sole
Dispositive Power    0 shares

10

Shared
Dispositive Power    4,018,603 shares

11

Aggregate Amount Beneficially Owned by
Each Reporting Person

4,018,603 shares

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)     ¨
13

Percent of Class Represented by Amount
in Row (11)

18.52%3

14

Type of Reporting Person (See Instructions)

PN (Limited Parntership)

3
Represents 2,256,071 shares of the common stock (“Common Stock”) of Dicerna Pharmaceuticals, Inc. (the
“Issuer”) and 1,762,532 shares of the Common Stock underlying the Preferred Stock (as defined below) attributable
to the Fund which constitute approximately 18.52% of the class outstanding. The percentage calculation assumes that there are
currently 20,794,193 outstanding shares of the Common Stock of the Issuer, based on the Issuer’s Form 10-K as filed
with the Securities and Exchange Commission (“SEC”) on March 30, 2017.

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)